Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for CANF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
December 31, 2023 6.243M
September 30, 2023 5.235M
June 30, 2023 6.874M
March 31, 2023 8.493M
December 31, 2022 4.472M
September 30, 2022 7.428M
June 30, 2022 9.892M
March 31, 2022 12.02M
December 31, 2021 14.38M
September 30, 2021 9.334M
June 30, 2021 3.955M
March 31, 2021 7.078M
December 31, 2020 6.074M
September 30, 2020 9.541M
June 30, 2020 9.156M
March 31, 2020 5.069M
December 31, 2019 0.877M
September 30, 2019 7.056M
June 30, 2019 8.441M
March 31, 2019 3.245M
December 31, 2018 3.015M
September 30, 2018 6.387M
June 30, 2018 6.51M
March 31, 2018 7.429M
December 31, 2017 5.014M
Date Value
September 30, 2017 3.463M
June 30, 2017 4.015M
March 31, 2017 5.792M
December 31, 2016 3.863M
September 30, 2016 5.853M
June 30, 2016 7.732M
March 31, 2016 9.252M
December 31, 2015 10.35M
September 30, 2015 6.872M
June 30, 2015 4.697M
March 31, 2015 5.962M
December 31, 2014 6.486M
September 30, 2014 2.52M
June 30, 2014 4.085M
March 31, 2014 5.630M
December 31, 2013 3.810M
September 30, 2013 1.052M
June 30, 2013 0.6247M
March 31, 2013 1.685M
December 31, 2012 -1.245M
September 30, 2012 0.4132M
June 30, 2012 1.939M
March 31, 2012 1.813M
December 31, 2011 2.695M
September 30, 2011 0.2637M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
BioLineRx Ltd. 16.67M
XTL Biopharmaceuticals Ltd. --
Kamada Ltd. 269.56M
Galmed Pharmaceuticals Ltd. 13.95M
Revium Recovery, Inc. 18.10M